Natural Alternatives International (NAII) Competitors $3.21 0.00 (0.00%) As of 07/3/2025 02:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAII vs. MCRB, TCRX, VNRX, SRZN, EPIX, PLRX, MGNX, ZURA, ONCY, and QNCXShould you be buying Natural Alternatives International stock or one of its competitors? The main competitors of Natural Alternatives International include Seres Therapeutics (MCRB), TScan Therapeutics (TCRX), VolitionRx (VNRX), Surrozen (SRZN), ESSA Pharma (EPIX), Pliant Therapeutics (PLRX), MacroGenics (MGNX), Zura Bio (ZURA), Oncolytics Biotech (ONCY), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry. Natural Alternatives International vs. Its Competitors Seres Therapeutics TScan Therapeutics VolitionRx Surrozen ESSA Pharma Pliant Therapeutics MacroGenics Zura Bio Oncolytics Biotech Quince Therapeutics Seres Therapeutics (NASDAQ:MCRB) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership. Is MCRB or NAII more profitable? Seres Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -6.56%. Natural Alternatives International's return on equity of -10.34% beat Seres Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Seres TherapeuticsN/A -41,084.76% -55.87% Natural Alternatives International -6.56%-10.34%-5.19% Do institutionals & insiders believe in MCRB or NAII? 59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are held by institutional investors. 4.7% of Seres Therapeutics shares are held by company insiders. Comparatively, 20.9% of Natural Alternatives International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend MCRB or NAII? Seres Therapeutics currently has a consensus price target of $73.67, indicating a potential upside of 548.76%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Seres Therapeutics is more favorable than Natural Alternatives International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75Natural Alternatives International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor MCRB or NAII? In the previous week, Natural Alternatives International had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Natural Alternatives International and 0 mentions for Seres Therapeutics. Natural Alternatives International's average media sentiment score of 0.81 beat Seres Therapeutics' score of 0.00 indicating that Natural Alternatives International is being referred to more favorably in the news media. Company Overall Sentiment Seres Therapeutics Neutral Natural Alternatives International Positive Which has more risk & volatility, MCRB or NAII? Seres Therapeutics has a beta of 2.75, suggesting that its stock price is 175% more volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Which has better valuation & earnings, MCRB or NAII? Seres Therapeutics has higher revenue and earnings than Natural Alternatives International. Seres Therapeutics is trading at a lower price-to-earnings ratio than Natural Alternatives International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeres Therapeutics$126.32M0.78$140K-$4.60-2.47Natural Alternatives International$113.80M0.17-$7.22M-$1.39-2.31 SummarySeres Therapeutics beats Natural Alternatives International on 9 of the 16 factors compared between the two stocks. Get Natural Alternatives International News Delivered to You Automatically Sign up to receive the latest news and ratings for NAII and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAII vs. The Competition Export to ExcelMetricNatural Alternatives InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.08M$2.43B$5.53B$9.05BDividend YieldN/A1.78%5.24%4.03%P/E Ratio-2.318.9827.5220.22Price / Sales0.17682.84421.02118.64Price / CashN/A158.5936.8958.07Price / Book0.244.588.045.67Net Income-$7.22M$31.34M$3.18B$249.13M7 Day Performance-0.31%3.25%2.90%3.28%1 Month Performance-5.89%7.08%3.70%5.55%1 Year Performance-42.06%0.17%36.15%21.12% Natural Alternatives International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAIINatural Alternatives International1.0507 of 5 stars$3.21flatN/A-42.3%$20.08M$113.80M-2.31290MCRBSeres Therapeutics3.0636 of 5 stars$11.11+22.1%$73.67+563.1%-19.1%$79.46M$126.32M-2.42330High Trading VolumeTCRXTScan Therapeutics1.991 of 5 stars$1.45+3.6%$7.80+437.9%-74.2%$79.23M$2.82M-1.33100VNRXVolitionRx1.6924 of 5 stars$0.76-9.3%$3.50+360.5%+22.5%$78.30M$1.31M-2.1180SRZNSurrozen2.4077 of 5 stars$8.94-0.9%$38.50+330.6%-19.1%$77.24M$10.65M-0.3680Gap DownHigh Trading VolumeEPIXESSA Pharma1.3226 of 5 stars$1.70-1.7%$2.00+17.6%-63.7%$76.79MN/A-2.7050News CoveragePLRXPliant Therapeutics3.9983 of 5 stars$1.16-7.2%$13.31+1,047.6%-88.2%$76.73M$1.58M-0.3290High Trading VolumeMGNXMacroGenics4.1131 of 5 stars$1.21+1.7%$5.71+372.3%-65.7%$75.08M$149.96M-1.36430Gap UpZURAZura Bio3.3195 of 5 stars$1.05flat$14.33+1,265.1%-67.6%$71.79MN/A-1.503Positive NewsGap UpONCYOncolytics Biotech1.2147 of 5 stars$0.77+3.0%$4.33+460.6%-10.8%$70.77MN/A-2.6730QNCXQuince Therapeutics2.9989 of 5 stars$1.65+6.5%$8.00+384.8%+129.1%$70.48MN/A-1.1960 Related Companies and Tools Related Companies Seres Therapeutics Competitors TScan Therapeutics Competitors VolitionRx Competitors Surrozen Competitors ESSA Pharma Competitors Pliant Therapeutics Competitors MacroGenics Competitors Zura Bio Competitors Oncolytics Biotech Competitors Quince Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAII) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natural Alternatives International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Natural Alternatives International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
